Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $12 from $17 and keeps an Equal Weight rating on the shares. With Gr4 liver enzyme AE developing into a Gr5 event, the firm thinks there could be increased uncertainty in the nex-z program. Wells awaits clarity on potential cause to assess full implication as well as potential requirements for resuming studies.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $21 from $29 at Citizens JMP
- Intellia Therapeutics price target lowered to $14 from $24 at Barclays
- Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty
- Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan
- Intellia Therapeutics: Buy Rating Affirmed Amid HAE Program Optimism Despite ATTR Setback